SEARCH

SEARCH BY CITATION

References

  • 1
    Bosch FX, Ribes J, Borràs. J. Epidemiology of primary liver cancer. Sem Liver Dis 1999; 19: 27185.
  • 2
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 42130.
  • 3
    Giovannini M, Elias D, Monges G, et al. Hepatocellular carcinoma. Br J Cancer 2001; 84(Suppl. 2): 747.
  • 4
    Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 51924.
  • 5
    Roche A. Therapy of HCC-TACE for liver tumor. Hepato-Gastroenterology 2001; 48: 37.
  • 6
    Ramsey DE, Kernagis LY, Soulen MC,et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13: S211S221.
  • 7
    The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2003; 31: 8405.
  • 8
    Ueno S, Tanabe G, Sako K,et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: 52934.
  • 9
    Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child–Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 8815.
  • 10
    Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 46470.
  • 11
    Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52: 1349.
  • 12
    Wiesner R, Edwards E, Freeman R, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 916.
  • 13
    Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma – an impossible meta analysis? Aliment Pharmacol Ther 1998; 12: 11126.
  • 14
    Trevisani F, De Notariis S, Rossi C, et al. Randomized control trials on chemoembolization for hepatocellular carcinoma. Is there room for new studies? J Clin Gastroenterol 2001; 32: 3839.
  • 15
    Alsowmely AM, Hodgson HJF. Review article: non-surgical treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2002; 16: 115.
  • 16
    Lo C, Ngan H, Tso W, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 116571.
  • 17
    Llovet JM, Real MI, Montana X , et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 17349.
  • 18
    Kaasa S, Loge JH. Quality-of-life assessment in palliative care. Lancet Oncol 2002; 3: 17582.
  • 19
    Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 4754.
  • 20
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 42942.
  • 21
    Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of the therapeutic trials. Hepatology 1999; 29: 627.
  • 22
    Llado′ L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 507.
  • 23
    Farinati F, Rinaldi M, Gianni S, et al. How should patients with hepatocellular carcinoma be staged? Cancer 2000; 89: 226673.
  • 24
    Brian IC. Hepatic artery chemoembolization for advanced stage HCC. Experience of 650 patients. Hepato-Gastroenterology 2002; 49: 7986.
  • 25
    Everson GT. MELD: the answer or just more questions? Gastroenterology 2003; 124: 2514.
  • 26
    Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. Cancer 1995; 75: 242734.
  • 27
    Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial Lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 174752.
  • 28
    Huang YS, Chiang JH, Wu JC, et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethyglycinexylidide. Am J Gastroenterol 2002; 97: 12237.
    Direct Link:
  • 29
    Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51: 45962.
  • 30
    Giannini E, Romagnoli P, Fasoli A, et al. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age Ageing 2002; 31: 45762.
  • 31
    Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2002; 17: S428S433.
  • 32
    Befeler AS, Di Bisceglie M. Hepatocellular carcinoma. Diagnosis and treatment Gastroenterology 2002; 122: 160919.
  • 33
    Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol 2002; 35(Suppl. 2): S138S142.
  • 34
    Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38: S136S149.